Medical treatment of male infertility

Abstract

The reasons of male infertility are pretesticular, testicular and posttesticular. Medical treatment is suitable for the men with infertility due to pretesticular and testicular reasons. However, some of the infertile men may be found a reason while no reason is detected in some of infertile men. Therefor, specific treatment is given to infertile men who is found a specific reason while ampiric treatment is given to infertile men who is found no reason.

Keywords

• infertility
• male
• medical treatment
• ampiric

Erkek infertilitesinin medikal tedavisi

Abstract

Erkek infertilitesinin nedenleri pretestiküler, testiküler ve posttestikülerdir. Medikal tedavi pretestiküler ve testiküler nedenlere bağlı infertilitesi olan erkeklerde uygundur. Ancak infertil erkeklerin bazılarında bir neden bulunabilir iken kalan bir kısmında belirli bir neden saptanamamaktadır. Bu nedenle infertil erkeklerin medikal tedavisinde altta yatan neden biliniyor ise ona yönelik spesifik bir tedavi uygulanır iken bir nedeninin bulunamadığı olgularda ampirik medikal tedaviler verilmektedir.

Keywords

• infertilite
• erkek
• medikal tedavi
• ampirik

References

1. 1. Hamada A, Esteves SC, Nizza M, Agarwal A. Unexplained male infertility: diagnosis and management. Int Braz J Urol 2012; 38: 576-594.
2. 2. Jung JH, Seo JT. Empirical medical therapy in idiopathic male infertility: Promise or panacea? Clin Exp Reprod Med 2014; 41: 108-114.
3. 3. Dabaja AA, Schlegel PN. Medical treatment of male infertility. Trans Androl Urol 2014; 3: 9-16.
4. 4. Garg H, Kumar R. Empirical Drug Therapy for Idiopathic Male Infertility: What is the New Evidence? Urology 2015; 86: 1065-1075.
5. 5. Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol 2006; 176:1307-1312.
6. 6. Colacurci N, Monti MG, Fornaro F, et al. Recombinant human FSH reduces sperm DNA fragmentation in men with idiopathic oligoasthenoteratozoospermia. J Androl 2012; 33: 588-593.
7. 7. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2013; 8:CD005071.
8. 8. Jungwirth A, Diemer T, Dohle GR, Kopa Z, Krausz C, Tournaye H. The EAU Male Infertility Guidelines 2015.

9. 9. Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 2012; 98: 48-51.
10. 10. Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.. J Androl 1989; 10: 2:240-247.
11. 11. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001;165: 837-41.
12. 12. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002;167: 624-629.
13. 13. Başar MM, Tuğlu D. Aromatase inhibitors in infertile patients: effects on seminal parameters, serum and seminal plasma testosterone levels, and estradiol levels during shortterm follow-up. Turk J Med Sci 2009; 39: 519-524.
14. 14. Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011; 95: 809-811.
15. 15. Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of nonobstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl 2011; 15: 806-811.
16. 16. World Health Organization. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int J Androl 1992;15: 299-307.
17. 17. Cakan M, Aldemir M, Topcuoglu M, et al. Role of testosterone/ estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men. Urol Int 2009; 83: 446-45.1
18. 18. Moradi M, Moradi A, Alemi M, et al. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J 2010; 7: 188-193.
19. 19. Tang KF, Xing Y, Wu CY, et al. Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia. Zhonghua Nan KeXue 2011; 17: 615-618.
20. 20. Nada EA, El Taieb MA, Ibrahim HM, Al Saied AE. Efficacy of tamoxifen and L-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia. Andrologia 2014.
21. 21. Hussein A, Ozgok Y, Ross L, et al. Clomiphene administration for cases of non obstructive azoospermia: a multicenter study. J Androl 2005; 26: 787-791.
22. 22. Moein MR, Tabibnejad N, Ghasemzadeh J. Beneficial effect of tamoxifen on sperm recovery in infertile men with non obstructive azoospermia. Andrologia 2012; 44: 194-198.
23. 23. Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013; 1: 749-757.
24. 24. Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES Jr. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol 2012;187:973-8.
25. 25. Ross C, Morriss A, Khairy M, et al. A systematic review of the effect of oral antioxidants on male infertility. Ross et al. Reproductive BioMedicine Online 2010; 20, 711– 723.
26. 26. Shekarriz M, Thomas AJ Jr, Agarwal A. Incidence and level of seminal reactive oxygen species in normal men. Urology 1995; 45: 103-7.
27. 27. Agarwal A, Said TM. Role of sperm chromatin abnormalities and DNA damage in male infertility. Hum Reprod Update 2003; 9: 331-45.
28. 28. Venkatesh S, Shamsi MB, Deka D, Saxena V, Kumar R, Dada R. Clinical implications of oxidative stress & sperm DNA damage in normozoospermic infertile men. Indian J Med Res 2011; 134: 396-8.
29. 29. Agarwal A, Virk G, Ong C, du Plessis SS. Effect of oxidative stress on male reproduction. World J Mens Health 2014; 32: 1-17.
30. 30. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
31. 31. Griveau JF, Lannou D. Reactive oxygen species and human spermatozoa: physiology and pathology. Int J Urol 1997; 20: 61-69.
32. 32. Agarwal A, Makker K, Sharma R. Clinical relevance of oxidative stress in male factor infertility: an update. Am J Reprod Immunol 2008; 59: 2-11.
33. 33. Aitken RJ, Harkiss D, Buckingham DW. Analysis of lipid peroxidation mechanisms in human spermatozoa. Mol Reprod dev 1993; 35; 302-315.
34. 34. Agarwal A, Allamaneni SS, Said TM. Chemiluminescence technique for measuring reactive oxygen species. Reprod Biomed Online 2004; 9: 466-468.
35. 35. Cocuzza M, Agarwal A. Nonsurgical treatment of male infertility: specific and empiric therapy. Biologics 2007; 1: 259-69.
36. 36. Gharagozloo P, Aitken RJ. The role of sperm oxidative stress in male infertility and the significance of oral antioxidant therapy. Hum Reprod 2011; 26: 1628–1240.
37. 37. Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev 2014;12:CD007411.